Denis Petro, M.D.Founding Director
Dr. Petro is a board-certified neurologist with over 30 years experience in pharmaceutical research and development and medical practice. He began his post-residency career at the FDA and conducted the FDA Advisory meeting which defined the use of aspirin as primary prevention of stroke and advised Congress in writing the Orphan Drug Act of 1983. He conducted the first study of a cannabinoid (THC) in treatment of muscle spasms in spasticity, While working with the pharmaceutical industry, he developed a number of drugs for treatment of Parkinson’s Disease, chronic pain, depression, cognitive impairment and seizure disorders. He testified in support of medicinal cannabis at the DEA Rescheduling Hearing in 1986 and consulted with the Institute of Medicine in preparation of the IOM report on Medical Marijuana in 1997. He has been recognized as an expert in neurology and pharmacology by both the state and federal court systems of the USA, as well as in Canada and the United Kingdom.